TG Therapeutics has been ranked number 27 on Deloitte’s Technology Fast 500, recognizing its rapid North American revenue growth from 2021 to 2024, driven primarily by Briumvi, its anti-CD20 therapy approved in late 2022 for relapsing forms of multiple sclerosis. The accolade marks a commercial milestone for a company that transitioned from clinical-stage uncertainty to meaningful market traction in a high-bar neurology category.
The strategic question is whether recognition for velocity can translate into durable market share in an entrenched class dominated by far larger players. Briumvi competes head-to-head with Roche’s Ocrevus and Novartis’s Kesimpta, each with distinct channel and administration advantages. TG’s pitch has centered on faster infusion logistics and a cost position designed to undercut incumbents, a combination intended to resonate with neurologists and infusion centers pressed for capacity and predictability. As utilization grows, the company must demonstrate that operational convenience and economics are sufficient to shift prescribing behavior at scale without compromising safety or payer alignment.
This matters now because anti-CD20 agents have become the de facto backbone of RMS therapy, and share shifts within the class move real dollars across sites of care. For patients and HCPs, the trade-offs are practical: office-based Part B infusions with buy-and-bill economics versus at-home subcutaneous administration under pharmacy benefit management. Infusion centers may welcome a shorter chair time that increases throughput, while health systems and payers weigh total cost of care, adherence, and relapse prevention. Expect continued pressure from utilization management, site-of-care steering, and negotiated parity across the class, particularly as payers seek to avoid open-ended escalation in neurology budgets.
Medical Affairs will be pivotal to sustain momentum. The class carries well-characterized risks tied to B-cell depletion, and long-term confidence will hinge on robust real-world evidence around infections, immunoglobulin trends, liver signals, and adherence outside controlled trials. Clear guidance on vaccine timing, pregnancy considerations, and infusion reaction management can differentiate support quality in the eyes of community neurologists. TG’s development of a subcutaneous ublituximab and efforts to streamline initiation dosing aim to further reduce onboarding friction; success here could narrow Kesimpta’s convenience advantage and reinforce persistence, but it also invites heightened scrutiny from payers who may demand head-to-head or high-quality comparative effectiveness data before revising policies.
For competitors, TG’s ascent reinforces that lifecycle strategy and channel execution are now as decisive as pivotal data. Contracting and access optimization will intensify, with incumbents leveraging scale and outcomes-based constructs to defend share. For investors and business development teams, the recognition signals that revenue-backed, lean commercialization models are viable, potentially resetting valuation frameworks for single-asset immunology companies and making TG a credible partner or acquisition candidate as neurology-immunology dealmaking accelerates.
The next 12 to 18 months will test whether TG can convert award-year momentum into structural advantages. Watch for payer coverage durability under both medical and pharmacy benefits, the pace and impact of subcutaneous and initiation-simplification programs, evidence generation that resonates with guideline authors and payers, and ex-US ramp quality. The core question for commercial and medical leaders across the category is whether operational convenience and targeted pricing can permanently reframe anti-CD20 share dynamics, or whether contracting muscle and at-home administration will reassert dominance as the class evolves.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
